報價延遲最少15分鐘:2026/01/09 09:42 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
13.48 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.84/-2.56
|
|
企業價值
442.67M
|
| 資產負債 |
|
每股賬面淨值
2.24
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
65.32M
|
|
每股收益
2.79
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue. |
